City

Newcastle (1)

Condition

Chronic Myelomonocytic Leukemia (2)

Higher Risk Myelodysplastic Syndrome (2)

Acute Myeloid Leukemia (1)

Recurrent Acute Myeloid Leukemia (1)

Refractory Acute Myeloid Leukemia (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (2)

Sponsor

Amgen (1)

Race Oncology Ltd (1)

Collaborator

Astex Pharmaceuticals, Inc. (1)

Intervention

amg 176 (1)

azacitidine (1)

bisantrene dihydrochloride (high dose) (1)

bisantrene dihydrochloride (low dose) (1)

cytarabine hydrochloride (1)

decitabine and cedazuridine (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

higher risk myelodysplastic syndrome

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Trial (AMG 176, Azacitidine)

Not yet recruiting

Higher Risk Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

AMG 176
Azacitidine

(no location specified)

Jul 29, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Newcastle (Bisantrene DiHCl

Recruiting

Acute Myeloid Leukemia
+4 more

Bisantrene Dihydrochloride (high dose)
+3 more

Newcastle, New South Wales, Australia

Calvary Mater

Jul 14, 2022